Apellis Pharmaceuticals Inc

APLS

Add to Watchlist

41.030USD

0.0000.00%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Apellis Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

82 / 156

Overall Ranking

224 / 4487

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Apellis Pharmaceuticals Inc Highlights

StrengthsRisks

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 153.10% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 38.75, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 117.68M shares, decreasing 18.57% quarter-over-quarter.

Held by Joel Greenblatt

Star Investor Joel Greenblatt holds 168.46K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.50.

Analyst Rating

Based on 14 analysts

Hold

Current Rating

39.722

Target Price

-3.19%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Its latest quarterly revenue reached 268.30M, representing a year-over-year increase of 60.85%, while its net profit experienced a year-over-year increase of 120.23%.

Score

Industry at a Glance

Previous score

8.10

Change

0



Financials

8.21

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.04

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

9.89

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.03

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.34

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Apellis Pharmaceuticals Inc is 7.55, ranking 64 out of 156 in the Pharmaceuticals industry. Its current P/E ratio is 38.75, which is 497.84% below the recent high of 231.69 and 155.95% above the recent low of -21.68.

Score

Industry at a Glance

Previous score

7.55

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 82/156

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Apellis Pharmaceuticals Inc is 6.48, ranking 132 out of 156 in the Pharmaceuticals industry. The average price target is 36.00, with a high of 55.00 and a low of 19.00.

Score

Industry at a Glance

Previous score

6.48

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Apellis Pharmaceuticals Inc is 3.16, ranking 151 out of 156 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 41.18 and the support level at 40.84, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.46

Change

-0.3

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-13

The latest institutional shareholding proportion is 91.92%, representing a quarter-over-quarter decrease of 21.19%. The largest institutional shareholder is Scotia Canadian Dividend Fund, holding a total of 1.07M shares, representing 0.84% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Morningside Venture Investments, Ltd.

12.81M

--

Avoro Capital Advisors LLC

12.22M

--

Morgan Stanley & Co. LLC

8.90M

-3.12%

Deep Track Capital LP

7.75M

-3.13%

RTW Investments L.P.

7.67M

--

State Street Investment Management (US)

4.61M

+14.26%

UBS Financial Services, Inc.

4.12M

+19.98%

BlackRock Institutional Trust Company, N.A.

5.46M

+2.28%



1

2



Apellis Pharmaceuticals Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Apellis Pharmaceuticals Inc

APLS

6.54 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Catalyst Pharmaceuticals Inc

CPRX

9.11 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Jazz Pharmaceuticals PLC

JAZZ

8.81 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Kiniksa Pharmaceuticals International PLC

KNSA

8.59 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

8.52 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment